Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/30/2012 | 10:20pm CET

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HALOZYME THERAPEUTICS, INC
01/12 HALOZYME THERAPEUTICS : Announces Phase 2 Study In Advanced Pancreas Cancer Meet..
01/10 HALOZYME THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and E..
01/09 HALOZYME THERAPEUTICS INC : Results of Operations and Financial Condition, Regul..
01/09 HALOZYME THERAPEUTICS : Provides Program Updates, 2017 Financial Guidance At 35t..
01/09 HALOZYME THERAPEUTICS, INC. : Biotech Industry Off to a Strong Start in 2017 Lat..
01/05 HALOZYME THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (for..
01/05 HALOZYME THERAPEUTICS : Announces Phase 2 Study In Advanced Pancreas Cancer Meet..
2016 HALOZYME THERAPEUTICS : To Present At The 35th Annual J.P. Morgan Healthcare Con..
2016 HALOZYME THERAPEUTICS : New SCIEX Webinar to Discuss Advancements in NLinked Gly..
2016 HALOZYME THERAPEUTICS : New SCIEX Webinar to Discuss Advancements in N‐Lin..
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
01/09 Halozyme down 5.9% after hours on 2017 guidance
01/06 Trump Rally Took A Break - Cramer's Mad Money (1/5/17)
01/05 Midday Gainers / Losers
01/05 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
01/05 TheStreet's Feuerstein says Halozyme selective in data read-out from mid-stag..